Personalized approaches to active immunotherapy in cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1865, Issue 1, 2016, Pages 72-82

  Ophir, Eran ^a   Bobisse, Sara ^a   Coukos, George ^a,c   Harari, Alexandre ^a,b   Kandalaft, Lana E ^a,b,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Ludwig Center for Cancer Research   (Switzerland)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer vaccines; Dendritic cells; Neo antigens; Personalized vaccines; Tumor associated antigens; Whole tumor vaccines

Indexed keywords

BELAGENPUMATUCEL L; CANCER VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MELANOMA ANTIGEN 3; NY ESO 1 ANTIGEN; SUNITINIB; TECEMOTIDE; AUTOANTIGEN; NANOPARTICLE; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ADVANCED CANCER; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; DENDRITIC CELL; DISEASE ERADICATION; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; KIDNEY CANCER; LUNG CANCER; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ACTIVE IMMUNOTHERAPY; IMMUNOLOGY; NEOPLASMS;

ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ACTIVE; NANOPARTICLES; NEOPLASMS; PRECISION MEDICINE;

EID: 84958902312     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.07.004     Document Type: Article

References (186)

1. Melero I., et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 2014, 11(9):509-524.
2. Schiller J.T., Muller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 2015, 16(5):e217-e225.
3. Finn O.J. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol. Res. 2014, 2(8):708-713.
4. Agosti J.M., Goldie S.J. Introducing HPV vaccine in developing countries-key challenges and issues. N. Engl. J. Med. 2007, 356(19):1908-1910.
5. Garland S.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007, 356(19):1928-1943.
6. Group F.I.S. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 2007, 356(19):1915-1927.
7. Aranda F., et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013, 2(12):e26621.
8. Hanna M.G., et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001, 19(17-19):2576-2582.
9. Schellhammer P.F., et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013, 81(6):1297-1302.
10. Hale D.F., et al. Cancer vaccines: should we be targeting patients with less aggressive disease?. Expert Rev. Vaccines 2012, 11(6):721-731.
11. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10(9):909-915.
12. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480(7378):480-489.
13. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392(6673):245-252.
14. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
15. + regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 2007, 204(1):191-201.
16. de Chaisemartin L., et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 2011, 71(20):6391-6399.
17. Williams M.A., et al. Developing and maintaining protective CD8+ memory T cells. Immunol. Rev. 2006, 211:146-153.
18. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005, 434(7029):88-93.
19. Perez-Diez A., et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007, 109(12):5346-5354.
20. Quezada S.A., et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 2010, 207(3):637-650.
21. + T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies. Tissue Antigens 2014, 83(4):237-246.
22. Motz G.T., Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013, 39(1):61-73.
23. Motz G.T., et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 2014, 20(6):607-615.
24. Buckanovich R.J., et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 2008, 14(1):28-36.
25. Piali L., et al. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 1995, 181(2):811-816.
26. Griffioen A.W., et al. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 1996, 56(5):1111-1117.
27. Bellone M., Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol. 2013, 3:231.
28. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007, 117(5):1147-1154.
29. Lippitz B.E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013, 14(6):e218-e228.
30. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12(4):252-264.
31. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 2006, 6(4):295-307.
32. Montero A.J., et al. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. Immunother. 2012, 35(2):107-115.
33. Heemskerk B., Kvistborg P., Schumacher T.N. The cancer antigenome. EMBO J. 2013, 32(2):194-203.
34. Coulie P.G., et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 2014, 14(2):135-146.
35. Simpson A.J., et al. Cancer/testis antigens, gametogenesis and cancer. Nat. Rev. Cancer 2005, 5(8):615-625.
36. Alexandrov L.B., et al. Signatures of mutational processes in human cancer. Nature 2013, 500(7463):415-421.
37. Lawrence M.S., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499(7457):214-218.
38. Rammensee H.G., Singh-Jasuja H. HLA ligandome tumor antigen discovery for personalized vaccine approach. Expert Rev. Vaccines 2013, 12(10):1211-1217.
39. Trajanoski Z., et al. Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. Cancer Immunol. Immunother. 2015, 64(1):99-104.
40. Castle J.C., et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012, 72(5):1081-1091.
41. Matsushita H., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482(7385):400-404.
42. Yadav M., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014, 515(7528):572-576.
43. Robbins P.F., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013, 19(6):747-752.
44. van Rooij N., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 2013, 31(32):e439-e442.
45. Wick D.A., et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin. Cancer Res. 2014, 20(5):1125-1134.
46. Snyder A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371(23):2189-2199. 10.1056/NEJMoa1406498.
47. Kreiter S., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015, 520(7549):692-696.
48. + T cells in human melanoma. Nat. Med. 2015, 21(1):81-85.
49. + T cells in a patient with epithelial cancer. Science 2014, 344(6184):641-645.
50. Lennerz V., et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(44):16013-16018.
51. Vogelstein B., et al. Cancer genome landscapes. Science 2013, 339(6127):1546-1558.
52. Rosenberg S.A., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998, 4(3):321-327.
53. Speiser D.E., et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(10):3849-3854.
54. + T cells in patients with melanoma. J. Immunol. 2005, 175(9):6169-6176.
55. Slingluff C.L. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?. Cancer J. 2011, 17(5):343-350.
56. Toes R.E., et al. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 1996, 156(10):3911-3918.
57. Toes R.E., et al. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(15):7855-7860.
58. Ulloa-Montoya F., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 2013, 31(19):2388-2395.
59. Vansteenkiste J.F., M.Z., Dahabreh I.J., Linder A., Lehmann F., Gruselle O., Therasse P., Louahed J., Brichard V.G. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2008, 26:a7501.
60. Vansteenkiste J.F., B.C., Vanakesa T., De Pas T., Zielinski M., Kim M.S., Jassem J., Yoshimura M., Dahabreh J., Nakayama H., Havel L., Kondo H., Mitsudomi T., Zarogoulidis K., Gladkov O.A., Spiessens B., Brichard V., Debruyne C., Therasse P., Altorki N., MAGRIT A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-a3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-a3-positive non-small cell lung cancer (NSCLC). Ann. Oncol. 2014, 25:a11730.
61. van der Bruggen P., Van den Eynde B.J. Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol. 2006, 18(1):98-104.
62. + T cells. J. Biol. Chem. 2009, 284(14):9184-9191.
63. Rosalia R.A., et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur. J. Immunol. 2013, 43(10):2554-2565.
64. Jandus C., Speiser D., Romero P. Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res. 2009, 22(6):711-723.
65. Kakimi K., et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int. J. Cancer 2011, 129(12):2836-2846.
66. Sabbatini P., et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 2012, 18(23):6497-6508.
67. Jandus C., P.B., Braun M., Derré L., Cagnon L., Rivals J.P., Rimoldi D., Romano E., Michielin O., Romero P., Speiser D.E. Vaccination With Long NY-ESO 79-108 Peptide in Combination With CpG Leads to Robust Activation of Both CD4 and CD8 T Cell Responses in Stage III and IV Melanoma Patients 2015, The Society for Immunotherapy of Cancer, Poster ID # 111850, 2015.
68. Kenter G.G., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 2009, 361(19):1838-1847.
69. Butts C., et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014, 15(1):59-68.
70. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 1996, 66(4):470-476.
71. Riker A., et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 1999, 126(2):112-120.
72. Brossart P., et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000, 96(9):3102-3108.
73. Disis M.L., et al. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. Immunol. 2004, 24(5):571-578.
74. Corbiere V., et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011, 71(4):1253-1262.
75. Banchereau J., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001, 61(17):6451-6458.
76. Walter S., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012, 18(8):1254-1261.
77. Yoshitake Y., et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin. Cancer Res. 2015, 21(2):312-321.
78. Bedke J., Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma. Expert Opin. Investig. Drugs 2013, 22(10):1329-1336.
79. Chiang C.L., Benencia F., Coukos G. Whole tumor antigen vaccines. Semin. Immunol. 2010, 22(3):132-143.
80. Neller M.A., Lopez J.A., Schmidt C.W. Antigens for cancer immunotherapy. Semin. Immunol. 2008, 20(5):286-295.
81. Hsueh E.C., et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J. Clin. Oncol. 1998, 16(9):2913-2920.
82. Hsueh E.C., et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J. Clin. Oncol. 2002, 20(23):4549-4554.
83. Drake C.G., Lipson E.J., Brahmer J.R. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat. Rev. Clin. Oncol. 2014, 11(1):24-37.
84. Raez L.E., et al. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther. 2003, 10(11):850-858.
85. Raez L.E., et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2004, 22(14):2800-2807.
86. Higano C.S., et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008, 113(5):975-984.
87. Le D.T., et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 2015, 33(12):1325-1333.
88. Nemunaitis J., et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 2006, 24(29):4721-4730.
89. Bazhenova Lyudmila, G.G., Nemunaitis John J., Juhász Erzsébet, Ramlau Rodryg, van den Heuvel Michel M., Lal Rohit, Dunlop David, Garon Edward B., Chu Quincy S., Mahendra Jain Minish, Carrier Ewa, Moses Steven, Shawler Daniel, Fakhrai Habib An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): updated analysis of patients enrolled within 12 weeks of completion of chemotherapy. J. Clin. Oncol. 2014, 32(5 s). (Suppl.; abstr 8056).
90. Andersen R.S., et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 2012, 72(7):1642-1650.
91. Linnemann C., Mezzadra R., Schumacher T.N. TCR repertoires of intratumoral T-cell subsets. Immunol. Rev. 2014, 257(1):72-82.
92. Gubin M.M., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515(7528):577-581.
93. Rajasagi M., et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014, 124(3):453-462.
94. Rizvi N.A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015, 348(6230):124-128.
95. Champiat S., et al. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014, 3(1):e27817.
96. Rooney M.S., et al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015, 160(1-2):48-61.
97. Fritsch E.F., Hacohen N., Wu C.J. Personal neoantigen cancer vaccines: the momentum builds. Oncoimmunology 2014, 3:e29311.
98. Carreno B.M., et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015, 348(6236):803-808.
99. Jocham D., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004, 363(9409):594-599.
100. Fishman M., et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J. Immunother. 2008, 31(1):72-80.
101. Burkhardt U.E., et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J. Clin. Invest. 2013, 123(9):3756-3765.
102. Vermorken J.B., et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999, 353(9150):345-350.
103. Solbrig C.M., et al. Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol. Pharm. 2007, 4(1):47-57.
104. Win S.J., et al. Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles. Br. J. Cancer 2012, 106(1):92-98.
105. Prasad S., et al. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine 2011, 7(1):1-10.
106. Joshi V.B., et al. Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev. Vaccines 2014, 13(1):9-15.
107. Silva J.M., et al. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J. Control. Release 2013, 168(2):179-199.
108. Krishnamachari Y., et al. Nanoparticle delivery systems in cancer vaccines. Pharm. Res. 2011, 28(2):215-236.
109. Park K. Mechanism of cross-presentation of microencapsulated antigen. J. Control. Release 2011, 151(3):219.
110. Panyam J., et al. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002, 16(10):1217-1226.
111. Hanlon D.J., et al. Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. Am. J. Reprod. Immunol. 2011, 65(6):597-609.
112. Yoshikawa T., et al. Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma. Biol. Pharm. Bull. 2006, 29(1):100-104.
113. Gross B.P., et al. A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer. AAPS J. 2014, 16(6):1194-1203.
114. Hamdy S., et al. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm. Res. 2011, 28(9):2288-2301.
115. Espuelas S., et al. Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. Bioconjug. Chem. 2008, 19(12):2385-2393.
116. Dhodapkar M.V., et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci. Transl. Med. 2014, 6(232):232ra51.
117. Reddy S.T., et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25(10):1159-1164.
118. Beaudette T.T., et al. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines. Mol. Pharm. 2009, 6(4):1160-1169.
119. Tacken P.J., et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011, 118(26):6836-6844.
120. Mueller M., et al. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice. J. Control. Release 2012, 162(1):159-166.
121. Anguille S., et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014, 15(7):e257-e267.
122. Palucka K., Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013, 39(1):38-48.
123. Butterfield L.H. Dendritic cells in cancer immunotherapy clinical trials: are we making progress?. Front. Immunol. 2013, 4:454.
124. Nestle F.O., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998, 4(3):328-332.
125. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 2012, 12(4):265-277.
126. Dillman R.O., et al. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J. Immunother. 2012, 35(8):641-649.
127. Yu J.S., et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004, 64(14):4973-4979.
128. Liau L.M., et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin. Cancer Res. 2005, 11(15):5515-5525.
129. Prins R.M., et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin. Cancer Res. 2011, 17(6):1603-1615.
130. Prokopowicz Z.M., et al. Hypochlorous acid: a natural adjuvant that facilitates antigen processing, cross-priming, and the induction of adaptive immunity. J. Immunol. 2010, 184(2):824-835.
131. Allison M.E., Fearon D.T. Enhanced immunogenicity of aldehyde-bearing antigens: a possible link between innate and adaptive immunity. Eur. J. Immunol. 2000, 30(10):2881-2887.
132. Callahan M.K., et al. Differential acquisition of antigenic peptides by Hsp70 and Hsc70 under oxidative conditions. J. Biol. Chem. 2002, 277(37):33604-33609.
133. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat. Immunol. 2002, 3(12):1129-1134.
134. Tatla S., et al. The role of reactive oxygen species in triggering proliferation and IL-2 secretion in T cells. Free Radic. Biol. Med. 1999, 26(1-2):14-24.
135. Anderson M.M., et al. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J. Clin. Invest. 1997, 99(3):424-432.
136. Carrasco-Marin E., et al. Oxidation of defined antigens allows protein unfolding and increases both proteolytic processing and exposes peptide epitopes which are recognized by specific T cells. Immunology 1998, 95(3):314-321.
137. Hazen S.L., et al. Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J. Clin. Invest. 1996, 98(6):1283-1289.
138. Chiang C.L., et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin. Cancer Res. 2013, 19(17):4801-4815.
139. Kandalaft L.E., et al. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J. Transl. Med. 2013, 11:149.
140. Gong J., et al. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 1997, 3(5):558-561.
141. Koido S., et al. Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology 2013, 2(5):e24437.
142. Koido S., et al. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol. 2002, 168(5):2111-2117.
143. Koido S., et al. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLoS One 2013, 8(3):e59280.
144. Gong J., Koido S., Calderwood S.K. Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev. Vaccines 2008, 7(7):1055-1068.
145. Avigan D., et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 2004, 10(14):4699-4708.
146. Kikuchi T., et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. 2004, 27(6):452-459.
147. Rosenblatt J., et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 2013, 19(13):3640-3648.
148. Gilboa E., Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 2004, 199:251-263.
149. Milazzo C., et al. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003, 101(3):977-982.
150. Benencia F., Courreges M.C., Coukos G. Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J. Transl. Med. 2008, 6:21.
151. Rea D., et al. Strategies for improved antigen delivery into dendritic cells. Trends Mol. Med. 2001, 7(3):91-94.
152. + T-cell responses and tumor immunity. Blood 2003, 102(12):4137-4142.
153. Su Z., et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 2003, 63(9):2127-2133.
154. Vik-Mo E.O., et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol. Immunother. 2013, 62(9):1499-1509.
155. sim Amin A.D., Logan Theodore, Lance Raymond S., Holzbeierlein Jeffrey M., Master Viraj A., Kumar Pal Sumanta, Knox Jennifer J., Ivan Karsh Lawrence, Plessinger Doug, Nicolette Charles A., Figlin Robert A. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). J. Clin. Oncol. 2013, 31(6):a357.
156. Amin A., et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J. Immunother. Cancer 2015, 3:14.
157. Schwartzentruber D.J., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011, 364(22):2119-2127.
158. Antonia S.J., Larkin J., Ascierto P.A. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin. Cancer Res. 2014, 20(24):6258-6268. 10.1158/1078-0432.
159. Page D.B., et al. Immune modulation in cancer with antibodies. Annu. Rev. Med. 2014, 65:185-202.
160. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363(8):711-723.
161. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366(26):2455-2465.
162. Hamid O., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369(2):134-144.
163. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369(2):122-133.
164. Hurwitz A.A., et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(17):10067-10071.
165. Curran M.A., et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(9):4275-4280.
166. Duraiswamy J., et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013, 73(12):3591-3603.
167. Kandalaft L.E., et al. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev. 2011, 30(1):141-151.
168. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 2011, 11(10):702-711.
169. Manning E.A., et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 2007, 13(13):3951-3959.
170. Shrimali R.K., et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010, 70(15):6171-6180.
171. Zhang L., et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Pathol. 2002, 161(6):2295-2309.
172. Bellone M., Calcinotto A., Corti A. Won't you come on in? How to favor lymphocyte infiltration in tumors. Oncoimmunology 2012, 1(6):986-988.
173. Calcinotto A., et al. Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J. Immunol. 2012, 188(6):2687-2694.
174. Johansson A., Hamzah J., Ganss R. Intratumoral TNFalpha improves immunotherapy. Oncoimmunology 2012, 1(8):1395-1397.
175. Johansson A., et al. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(20):7841-7846.
176. Facciabene A., Motz G.T., Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012, 72(9):2162-2171.
177. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 2013, 13(10):739-752.
178. Kusmartsev S., et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J. Immunol. 2008, 181(1):346-353.
179. Kandalaft L.E., et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013, 2(1):e22664.
180. Poschke I., et al. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Cancer Immunol. Immunother. 2014, 63(10):1061-1071.
181. Rapoport A.P., et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin. Cancer Res. 2014, 20(5):1355-1365.
182. Powell D.J., et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J. Immunol. 2006, 177(9):6527-6539.
183. + T cells. J. Exp. Med. 2005, 202(7):907-912.
184. Klebanoff C.A., et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005, 26(2):111-117.
185. Amos S.M., et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011, 118(3):499-509.
186. Attia P., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005, 23(25):6043-6053.